Sutro Biopharma, a clinical-stage oncology company, is making headlines with its innovative work in antibody drug conjugates (ADCs) through its proprietary protein synthesis platforms, XpressCF and XpressCF+. The company's product candidates, such as STRO-001, an ADC targeting CD74, and STRO-002, an ADC targeting folate receptor-alpha, are currently in Phase 1 clinical trials for patients with multiple myeloma, non-Hodgkin lymphoma, ovarian and endometrial cancers. In addition to these, Sutro's pre-clinical product candidate, STRO-003, is an ADC that targets ROR1 to treat solid tumors. Sutro has entered collaboration and license agreements with industry giants such as Merck Collaboration, Celgene Corporation, EMD Serono, and Astellas Pharma Inc. Formerly known as Fundamental Applied Biology, the company was founded in 2003 and is headquartered in South San Francisco, California.
StrongPoint's ticker is STRO
The company's shares trade on the NASDAQ stock exchange
They are based in South San Francisco, California
There are 51-200 employees working at StrongPoint
It is strongpoint.com/no
StrongPoint is in the Healthcare sector
StrongPoint is in the Biotechnology industry
The following five companies are StrongPoint's industry peers:
- Aeglea BioTherapeutics, Inc.